PBYI

Puma BiotechnologyB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

25%

Probability

Target price

$9.00

+28.9% vs current

Most likely

Base case

45%

Probability

Target price

$7.00

+0.3% vs current

B-

Bear case

30%

Probability

Target price

$5.00

-28.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This is a cautious T+1 post-earnings monitoring setup, not a strong thesis change. Primary company evidence improved with a clear guidance raise and debt elimination, but the evidence packet does not provide independently confirmed consensus surprise, post-print analyst revisions, or a durable market-reaction read-through. Coverage is thin, the quarter still showed year-over-year revenue pressure and higher R&D, and the reaction should be treated as constructive but not fully validated yet.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-05-08eventQ1 earnings raised full-year revenue and net income guidanceHigh impact

Puma's May 7, 2026 earnings release, furnished as Exhibit 99.1 to the May 7 Form 8-K, reported Q1 2026 total revenue of $44.8M, net product revenue of $42.0M, and a GAAP net loss of $3.8M. Management raised full-year 2026 total revenue guidance to $222M-$229M from $214M-$221M and net income guidance to $16M-$19M from $10M-$13M, citing increased NERLYNX demand [#8-K-2026-05-07].

2026-06-30catalystDebt elimination and stronger operating cash flow improve downside supportMedium impact

The Q1 earnings release reported $101.5M of cash, cash equivalents and marketable securities at March 31, 2026, $15.4M of operating cash flow in Q1, and a final May 4, 2026 payment under the 2021 Note Purchase Agreement that reduced outstanding debt to zero, supporting balance-sheet resilience even as quarterly earnings remain variable [#8-K-2026-05-07] [#10-Q-2026-05-07].

2026-12-31catalystAlisertib expansion and updated Phase II data are the main forward optionalityHigh impact

Management said it expects over the next 12 months to expand enrollment in ALISCA-Breast1 in H2 2026, expand ALISCA-Lung1 in H2 2026, and present updated ALISCA-Breast1 data in Q4 2026. That gives Puma a real pipeline option, but the milestones are still clinical and execution-dependent rather than near-certain value inflection points [#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology